Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter? Kelly GeorgeGillian Woollett Current Opinion Open access 06 August 2019 Pages: 447 - 451
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine Pavine L. C. LefevreLisa M. ShackeltonNiels Vande Casteele Leading Article 12 July 2019 Pages: 453 - 468
Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis Soohyun LeeHeeyoung LeeEunYoung Kim Systematic Review 24 August 2019 Pages: 469 - 483
Oncolytic Viruses: Priming Time for Cancer Immunotherapy Luke RussellKah Whye PengRosa Maria Diaz Review Article Open access 18 July 2019 Pages: 485 - 501
The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks Arash Hajizadeh DastjerdiAnthony NewmanGaetan Burgio Review Article 05 August 2019 Pages: 503 - 513
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies Lorraine SpringuelCaroline LonezFrédéric F. Lehmann Review Article Open access 30 July 2019 Pages: 515 - 537
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer Brittany L. Allen-PetersenRosalie C. Sears Review Article Open access 07 August 2019 Pages: 539 - 553
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study Niels ReinmuthMaciej BrylKazuo Kasahara Original Research Article Open access 23 July 2019 Pages: 555 - 570
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies Ellen Q. WangJack F. BukowskiDaniel Baltrukonis Original Research Article Open access 16 September 2019 Pages: 571 - 579
Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?” Christopher J. WebsterGillian R. Woollett Letter to the Editor Open access 01 August 2019 Pages: 581 - 582
Comment on: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis” Isabel Puértolas-TenaAlberto Frutos Pérez-Surio Letter to the Editor 09 October 2019 Pages: 583 - 584
Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis” Jichun YangShuqing YuFeng Sun Letter to the Editor 09 October 2019 Pages: 585 - 588
Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis Jichun YangShuqing YuFeng Sun Correction 21 September 2019 Pages: 589 - 594
